Industry partnerships strengthen biopharma innovation and manufacturing pathways

By Kevin Robinson | Published: 20-Feb-2026

The life sciences sector continues to embrace strategic collaborations that bridge discovery and manufacturing gaps, with two major announcements highlighting industry momentum in early 2026

You need to be a subscriber to read this article.
Click here to find out more.

In Germany, LEON‑nanodrugs and Harro Höfliger Verpackungsmaschinen GmbH have signed a strategic collaboration to expand the global distribution and after-sales support for LEON’s nanoencapsulation equipment, a platform increasingly central to advanced therapy manufacturing.

Under the terms of the agreement, Harro Höfliger will serve as a non-exclusive authorised partner to commercialise and service LEON’s FR-JET-based systems worldwide, providing pharmaceutical and biotech customers with broader access to scalable lipid nanoparticle (LNP) production technology.

This is seen as a critical enabler for modern biologics and RNA-based medicines

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like